Solving Kids Cancer Inc
Public records show a registered, tax-exempt organization in good standing.
Points to look into
- Only 40% of its spending went to programs.
- Raising each dollar of donations cost 88 cents.
These come from the organization's own tax return. There may be a good explanation; ask the charity.
What it says it does
SKC IMPACTS CHILDREN THROUGH THE INITIATION OF CLINICAL RESEARCH TRIALS OF INVESTIGATIVE TREATMENT STRATEGIES. OUR VISION IS TO CONTINUE EXPANDING THE ARMAMENTARIUM OF EFFECTIVE AND LESS TOXIC TREARTMENT STRATEGIES FOR PEDIATRIC ONCOLOGISTCS TO UTILIZE UNTIL LONG-TERM SURVIVAL IS A REALITY FOR ALL CHILDREN WITH HIGH-RISK SOLID TUMORS AND BRAIN TUMORS. TO ACCOMPLISH OUR MISSION, SKC FUNDS AND ADVOCATES FOR BREAKTHROUGH TREATMENT OPTIONS TO IMPROVE SURVIVAL OUTCOMES FOR CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS THROUGH COLLABORATIVE PARTNERSHIPS WITH THE RESEARCH COMMUNITY AND RELATED NONPROFIT STAKEHOLDERS.
- Income
- $333,401
- Spending
- $649,223
- Spent on programs
- 40%
- Reserves
- 4.5 months of spending
- Largest source of income
- donations and private grants, 82%
- Employees
- 3
- Volunteers
- 19
- Highest pay
- $157,018, former exec
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Weak: 40 out of 100. Higher than 5% of charities in its peer group (medical research, $250k to $1m).
Reserves
20 of 35Spendable reserves would cover 4.5 months of spending.
Debt
20 of 20It owes 8% of what it owns.
Living within its means
0 of 15Spending exceeded income by 95% of income.
Income trend
0 of 15Income fell 48% on the year before.
Spending floor
0 of 1540% of spending went to programs and raising each dollar of donations cost 88 cents.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 100 out of 100. Higher than 94% of charities in its peer group (medical research, $250k to $1m).
Independent board
25 of 2511 of 11 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (1)
- $262,005 spent. SKC LEADERSHIP AND SCIENTIFIC ADVISORS SURVEY, DISCUSS, AND PRIORITIZE THE AREAS OF GREATEST UNMET NEED WITHIN THE PEDIATRIC CANCER RESEARCH LANDSCAPE AND DEVELOP SPECIFIC PROGRAMS TO ADDRESS THEM. 1. SKC CONCEIVED AND ORGANIZED THE 2025 CARE FOR RARE GLOBAL STRATEGY FORUM, INVITING THE WORLD'S TOP EXPERTS IN EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES (ETMR) AND ATYPICAL TERATOID RHABDOID TUMOR (ATRT), TWO RARE AND AGGRESSIVE BRAIN TUMORS THAT AFFECT VERY YOUNG CHIILDREN. THE OBJECTIVES OF THE MEETING ARE TO FACILITATE THE EXCHANGE OF INFORMATION AROUND EXISTING RESEARCH PROJECTS AND BUILD COLLABORATIONS ACROSS CONTINENTS. 2. SKC INITIATED AND FACILITATED THE PEDIATRIC BRAIN TUMOR RESEARCH NETWORK (PBTRN) MEETINGS, BRINGING TOGETHER RESEARCHERS IN THE NYC AREA FROM THE TOP SIX INSTITUTIONS THREE TIMES PER YEAR TO SHARE RESEARCH DATA AND BUILD COLLABORATIONS. 3. SKC HAS ADVISORY ROLES ON NATIONAL AND INTERNATIONAL CLINICAL TRIALS CONSORTIA, REGULATORY BODIES, MULTI STAKEHOLDER PLATFORM FOR PEDIATRIC CANCER DRUG DEVELOPMENT, PHARMACEUTICAL COMPANIES, AND BUILDS COLLABORATIONS WITH OTHER NONPROFITS TO ADVOCATE FOR AND FUND RESEARCH. SKC REVIEWS PROPOSALS FOR THE NCI FUNDED CHILDREN'S ONCOLOGY GROUP AND THE DEPARTMENT OF DEFENSE RARE CANCER RESEARCH PROGRAMMATIC PANEL. SKC WAS INVITED TO SERVE ON PANELS AND PRESENT AT SEVEN SCIENTIFIC MEETINGS IN FIVE COUNTRIES. SKC CO-AUTHORED SEVERAL PEER-REVIEWED JOURNAL ARTICLES AND PEDIATRIC ONCOLOGY TEXTBOOK CHAPTERS. THESE ROLES GIVE SKC OPPORTUNITY TO INFLUENCE RESEARCH AGENDAS AND PRIORITIES. SKC LEADERSHIP AND SCIENTIFIC ADVISORS SURVEY, DISCUSS, AND PRIORITIZE THE AREAS OF GREATEST UNMET NEED WITHIN THE PEDIATRIC CANCER RESEARCH LANDSCAPE AND DEVELOP SPECIFIC PROGRAMS TO ADDRESS THEM. 1. SKC CONCEIVED AND ORGANIZED THE 2025 CARE FOR RARE GLOBAL STRATEGY FORUM, INVITING THE WORLD'S TOP EXPERTS IN EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES (ETMR) AND ATYPICAL TERATOID RHABDOID TUMOR (ATRT), TWO RARE AND AGGRESSIVE BRAIN TUMORS THAT AFFECT VERY YOUNG CHIILDREN. THE OBJECTIVES OF THE MEETING ARE TO FACILITATE THE EXCHANGE OF INFORMATION AROUND EXISTING RESEARCH PROJECTS AND BUILD COLLABORATIONS ACROSS CONTINENTS. 2. SKC INITIATED AND FACILITATED THE PEDIATRIC BRAIN TUMOR RESEARCH NETWORK (PBTRN) MEETINGS, BRINGING TOGETHER RESEARCHERS IN THE NYC AREA FROM THE TOP SIX INSTITUTIONS THREE TIMES PER YEAR TO SHARE RESEARCH DATA AND BUILD COLLABORATIONS. 3. SKC HAS ADVISORY ROLES ON NATIONAL AND INTERNATIONAL CLINICAL TRIALS CONSORTIA, REGULATORY BODIES, MULTI STAKEHOLDER PLATFORM FOR PEDIATRIC CANCER DRUG DEVELOPMENT, PHARMACEUTICAL COMPANIES, AND BUILDS COLLABORATIONS WITH OTHER NONPROFITS TO ADVOCATE FOR AND FUND RESEARCH. SKC REVIEWS PROPOSALS FOR THE NCI FUNDED CHILDREN'S ONCOLOGY GROUP AND THE DEPARTMENT OF DEFENSE RARE CANCER RESEARCH PROGRAMMATIC PANEL. SKC WAS INVITED TO SERVE ON PANELS AND PRESENT AT SEVEN SCIENTIFIC MEETINGS IN FIVE COUNTRIES. SKC CO-AUTHORED SEVERAL PEER-REVIEWED JOURNAL ARTICLES AND PEDIATRIC ONCOLOGY TEXTBOOK CHAPTERS. THESE ROLES GIVE SKC OPPORTUNITY TO INFLUENCE RESEARCH AGENDAS AND PRIORITIES.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated October 13, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2025.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since August 2007.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 21, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.